MAOYAN ENT (01896) intends to repurchase the company's shares.
MAOYAN ENT (01896) announced that the Board has resolved, subject to market conditions, to exercise the share repurchase mandate to repurchase shares on the open market from time to time, from the date of this announcement until the date of the Company's next annual general meeting to be held in 2027. The Company intends to use funds of not more than approximately HK$250 million to repurchase shares under the proposed share repurchase plan. The Company will fund the repurchases out of its existing available cash reserves and free cash flow.
MAOYAN ENT (01896) announced that the board of directors has resolved that, subject to market conditions, the company will exercise its share repurchase authorization to repurchase shares in the open market from time to time, from the date of this announcement until the date of the company's next annual general meeting of shareholders to be held in 2027. The company intends to use no more than approximately HK$250 million under the proposed share repurchase plan to repurchase shares. The company will fund the share repurchases using its existing available cash reserves and free cash flow.
Related Articles
CUTIA-B (02487) repurchased 40,800 shares for HK$39,700 on October 5.
AI compute demand outlook viewed favorably; BNP Paribas raises target prices for NVIDIA Corporation (NVDA.US) and Intel Corporation (INTC.US), but remains cautious on the latter.
SINOPHARM TECH (08156) restores public float
CUTIA-B (02487) repurchased 40,800 shares for HK$39,700 on October 5.
AI compute demand outlook viewed favorably; BNP Paribas raises target prices for NVIDIA Corporation (NVDA.US) and Intel Corporation (INTC.US), but remains cautious on the latter.
SINOPHARM TECH (08156) restores public float
